News & Presentations Filter by Category All 115 Company News 49 Media 23 Newsletter 9 Presentations & Webinars 36 Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Arovella presents at ISCT Dublin Read More Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Dr Nicole van der Weerden appointed acting CEO Read More Company News, All Michelle Long 4/5/26 Company News, All Michelle Long 4/5/26 Board refresh and CEO resignation Read More Company News, All Michelle Long 29/4/26 Company News, All Michelle Long 29/4/26 Appointment of Directors Read More Company News, All Michelle Long 20/4/26 Company News, All Michelle Long 20/4/26 Arovella presents poster at AACR Annual Meeting Read More Company News, All Michelle Long 15/4/26 Company News, All Michelle Long 15/4/26 Arovella receives additional R&D tax rebate of $0.28 million Read More Company News, All Michelle Long 1/4/26 Company News, All Michelle Long 1/4/26 CLDN18.2 CAR-iNKT cell preclinical data update Read More Company News, All Michelle Long 16/3/26 Company News, All Michelle Long 16/3/26 TGA clears ALA-101 trial under CTN scheme Read More Company News, All Michelle Long 9/2/26 Company News, All Michelle Long 9/2/26 Board Changes Read More Company News, All Michelle Long 5/2/26 Company News, All Michelle Long 5/2/26 Letter from Managing Director & CEO Read More Company News, All Michelle Long 29/1/26 Company News, All Michelle Long 29/1/26 Arovella’s IND for ALA-101 accepted by the U.S. Food and Drug Administration Read More Company News, All Michelle Long 30/12/25 Company News, All Michelle Long 30/12/25 Arovella files IND with the U.S. FDA for ALA-101 phase 1 clinical trial Read More Company News, All Michelle Long 12/11/25 Company News, All Michelle Long 12/11/25 Arovella appoints former CSL CSO Dr Andrew Nash as Non-executive Director Read More Company News, All Michelle Long 5/11/25 Company News, All Michelle Long 5/11/25 ALA exercises Option for Baylor College of Medicine assets Read More Company News, All Michelle Long 30/10/25 Company News, All Michelle Long 30/10/25 AGM 2025 presentation and results Read More Company News, All Michelle Long 29/10/25 Company News, All Michelle Long 29/10/25 Arovella progresses ALA-101 program with appointment of phase 1 CRO Read More Company News, All Michelle Long 28/10/25 Company News, All Michelle Long 28/10/25 Positive FDA Type D Meeting Outcome Read More Company News, All Bradley Cocks 2/10/25 Company News, All Bradley Cocks 2/10/25 CLDN18.2 CAR-T cells eliminate pancreatic cancer cells Read More Company News, All Bradley Cocks 2/10/25 Company News, All Bradley Cocks 2/10/25 Notice of Annual General Meeting | Thursday 30 October 2025, 11:00 am AEDT Read More Company News, All Bradley Cocks 23/9/25 Company News, All Bradley Cocks 23/9/25 Arovella Receives R&D Tax Rebate of $3,210,000 Read More Older Posts
Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Arovella presents at ISCT Dublin Read More
Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Dr Nicole van der Weerden appointed acting CEO Read More
Company News, All Michelle Long 4/5/26 Company News, All Michelle Long 4/5/26 Board refresh and CEO resignation Read More
Company News, All Michelle Long 29/4/26 Company News, All Michelle Long 29/4/26 Appointment of Directors Read More
Company News, All Michelle Long 20/4/26 Company News, All Michelle Long 20/4/26 Arovella presents poster at AACR Annual Meeting Read More
Company News, All Michelle Long 15/4/26 Company News, All Michelle Long 15/4/26 Arovella receives additional R&D tax rebate of $0.28 million Read More
Company News, All Michelle Long 1/4/26 Company News, All Michelle Long 1/4/26 CLDN18.2 CAR-iNKT cell preclinical data update Read More
Company News, All Michelle Long 16/3/26 Company News, All Michelle Long 16/3/26 TGA clears ALA-101 trial under CTN scheme Read More
Company News, All Michelle Long 9/2/26 Company News, All Michelle Long 9/2/26 Board Changes Read More
Company News, All Michelle Long 5/2/26 Company News, All Michelle Long 5/2/26 Letter from Managing Director & CEO Read More
Company News, All Michelle Long 29/1/26 Company News, All Michelle Long 29/1/26 Arovella’s IND for ALA-101 accepted by the U.S. Food and Drug Administration Read More
Company News, All Michelle Long 30/12/25 Company News, All Michelle Long 30/12/25 Arovella files IND with the U.S. FDA for ALA-101 phase 1 clinical trial Read More
Company News, All Michelle Long 12/11/25 Company News, All Michelle Long 12/11/25 Arovella appoints former CSL CSO Dr Andrew Nash as Non-executive Director Read More
Company News, All Michelle Long 5/11/25 Company News, All Michelle Long 5/11/25 ALA exercises Option for Baylor College of Medicine assets Read More
Company News, All Michelle Long 30/10/25 Company News, All Michelle Long 30/10/25 AGM 2025 presentation and results Read More
Company News, All Michelle Long 29/10/25 Company News, All Michelle Long 29/10/25 Arovella progresses ALA-101 program with appointment of phase 1 CRO Read More
Company News, All Michelle Long 28/10/25 Company News, All Michelle Long 28/10/25 Positive FDA Type D Meeting Outcome Read More
Company News, All Bradley Cocks 2/10/25 Company News, All Bradley Cocks 2/10/25 CLDN18.2 CAR-T cells eliminate pancreatic cancer cells Read More
Company News, All Bradley Cocks 2/10/25 Company News, All Bradley Cocks 2/10/25 Notice of Annual General Meeting | Thursday 30 October 2025, 11:00 am AEDT Read More
Company News, All Bradley Cocks 23/9/25 Company News, All Bradley Cocks 23/9/25 Arovella Receives R&D Tax Rebate of $3,210,000 Read More
